BOHLIN GAREN G 4

What Happened
Garen G. Bohlin, a director of Collegium Pharmaceutical, was granted 8,741 restricted stock units (RSUs) on May 14, 2026. The grant price is $0.00 (an award/compensation grant), so no cash changed hands at grant. The RSUs represent contingent rights to receive one share of common stock per RSU when they vest.

Key Details

• Transaction date: 2026-05-14; Transaction type/code: Award (A). Grant price reported as $0.00.
• Vesting/settlement: RSUs vest on the earlier of May 14, 2027 or the Issuer’s 2027 Annual Meeting, subject to continued board service. RSUs will be settled in shares on the vesting date or, at the director’s election, earlier upon end of service, death/disability, or a change in control. (See footnote F1.)
• Shares owned after transaction: Not reported in the filing.
• Filing: Form 4 filed 2026-05-18 (within the two-business-day reporting window).
• Other: Filing includes Exhibit 24.1 (Power of Attorney).

Context: RSU grants are a common form of board compensation and do not represent an immediate purchase or sale of stock. They create a future right to receive shares if vesting conditions are met, so they are not a direct signal of an insider buying or selling stock today.